↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Träfflista för sökning "WFRF:(Schulman Claude C.) "

Search: WFRF:(Schulman Claude C.)

Result 1-2 of 2

Sort/group result

Sort by: Hits per page:

Enumeration	Reference	Cover	Find
1.	Carducci, Michael A., et al. (author) A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer 2007 In: Cancer. - : Wiley. - 1097-0142 .- 0008-543X. ; 110:9, s. 1959-1966 Journal article (peer-reviewed)abstract BACKGROUND. The objective of this study was to evaluate the efficacy and safety of atrasentan (Xinlay), a selective endothelin-A receptor antagonist, in patients with metastatic hormone- refractory prostate cancer (HRPC). METHODS. This multinational, double-blind, placebo-controlled trial enrolled 809 men with metastatic HRPC. Patients were randomized 1:1 to receive either atrasentan 10 mg per day or placebo. The primary endpoint was time to disease progression (TTP), which was determined according to radiographic and clinical measures. Analyses of overall survival and changes in biomarkers also were performed. RESULTS. Atrasentan did not reduce the risk of disease progression relative to placebo (hazards ratio, 0.89; 95% confidence interval, 0.76-1.04; P =.136). Most patients progressed radiographically at the first 12-week bone scan without concomitant clinical progression. In exploratory analyses, increases from baseline to final bone alkaline phosphatase (BAP) and prostate-specific antigen (PSA) levels were significantly lower with atrasentan treatment (P <.05 for each). The median time to BAP progression (> 50% increase from nadir) was twice as long with atrasentan treatment (505 days vs 254 days; P <.01). The delay in time to PSA progression did not reach statistical significance. Atrasentan generally was tolerated well, and the most common adverse events associated with treatment were headache, rhinitis, and peripheral edema, reflecting the vasodilatory and fluid-retention properties of endothelin-A receptor antagonism. CONCLUSIONS. Atrasentan did not delay disease progression in men with metastatic HRPC despite evidence of biologic effects on PSA and BAP as markers of disease burden.
2.	Greenberg, Steven M., et al. (author) 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association 2022 In: STROKE. - 0039-2499 .- 1524-4628. ; 53:7 Journal article (peer-reviewed)

Skapa referenser, mejla, bekava och länka

Permalink

Result 1-2 of 2

Refine your search

Type of publication: journal article (2)

Type of content: peer-reviewed (2)

Author/Editor: Abrahamsson, Per-And ... (1); Stibrant Sunnerhagen ... (1); Cordonnier, Charlott ... (1); Goldstein, Joshua N. (1); Greenberg, Steven M. (1); Carducci, Michael A (1); show more...; Sprigg, Nikola (1); Saad, Fred (1); Schulman, Sam (1); Dearnaley, David R. (1); Schulman, Claude C. (1); North, Scott A. (1); Sleep, Darryl J. (1); Isaacson, Jeffrey D. (1); Nelson, Joel B. (1); Sheth, Kevin N. (1); Mocco, J (1); Ziai, Wendy C. (1); Dowlatshahi, Dar (1); Francis, Brandon (1); Hemphill, J. Claude (1); Johnson, Ronda (1); Keigher, Kiffon M. (1); Mack, William J. (1); Newton, Eileena J. (1); Ruff, Ilana M. (1); Sansing, Lauren H. (1); Selim, Magdy H. (1); show less...

University: University of Gothenburg (1); Lund University (1)

Language: English (2)

Research subject (UKÄ/SCB): Medical and Health Sciences (2)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - National Library Systems
LIBRIS.kb.se

pil uppåt

Close

Copy and save the link in order to return to this view